key: cord-0990328-ipth1iw5
authors: Carlson, Samantha J.; McKenzie, Lara; Roberts, Leah; Blyth, Christopher C.; Attwell, Katie
title: Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigation
date: 2021-12-16
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.12.021
sha: f74701e71a2c4949651091e9409051a9fcf01f18
doc_id: 990328
cord_uid: ipth1iw5

BACKGROUND: On 8(th) April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged <50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions. METHOD: we undertook qualitative interviews from February – April 2021 before and after the program change with 28 adults in Perth, Western Australia. Using our COVID-19 vaccine intentions model, we assessed changes in participants’ COVID-19 vaccine intention before and after the program change. Participants were classified as 1) ‘acceptors’: no concerns about COVID-19 vaccine safety, efficacy, access and would accept whatever vaccine is offered, 2) ‘cautious acceptors’: some concerns and would prefer a particular vaccine brand but would accept whatever is offered, 3) ‘Wait awhile’: for more data, easier access, for another vaccine brand, or a greater perceived COVID-19 threat or 4) ‘refuser’: no intention to vaccinate due to concerns about safety and/or efficacy. RESULTS: before the change, 7/18 of those aged <50 years were ‘acceptors,’ 10/18 were ‘cautious acceptors’ and 1/18 was ‘wait awhile.’ Overall, 14/18 participants had the same COVID-19 vaccine intention after the change; 4/18 became more concerned. For those aged ≥50 years and before the change, 5/10 were ‘acceptors’ and 5/10 were ‘cautious acceptors.’ After the change, 8/10 still had the same COVID-19 vaccine intention; 2/10 became more cautious. The major concern before the program change was COVID-19 vaccines having different vaccine efficacy; the concern pivoted to safety. CONCLUSION: the majority of participants were ‘cautious acceptors’ who intended on being vaccinated; many had this intention before and after the program change. The Australian government, health care providers and media need to better address COVID-19 vaccine concerns to assist those with COVID-19 vaccine intentions receive a vaccine.

To control the spread and the associated burden of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Diseases 2019 (COVID- 19) vaccination programs need to be safe and effective. Vaccine programs also need to be accessible and acceptable. In 2020, several Australian studies quantified COVID-19 vaccine intentions before COVID-19 vaccines were available in Australia: overall, there was relatively high intention to vaccinate in Australia, with approximately 4/5 adults indicating a willingness to be vaccinated. [1] [2] [3] Australia commenced vaccinating those deemed at highest risk of COVID-19 with the vaccine by Pfizer-BioNtech (Comirnaty) on the 22 nd of February 2021. Three weeks later, doses of the AstraZeneca vaccine were also being distributed and administered, with local production of this vaccine to constitute the cornerstone of Australia's supply. Soon after, on the 18 th of March, the European Medicines Agency (EMA) reported that the AstraZeneca "may be associated with very rare cases of blood clots associated with thrombocytopenia." 4 On the 2 nd of April, the Australian Technical Advisory Group of Immunisation (ATAGI) reported the first probable case in Australia. 5 This adverse event following immunisation (AEFI) is now called thrombosis with thrombocytopenia syndrome (TTS) which, at the time of writing, is reported in Australia in 3.1 per 100,000 adults aged <50 years, and 1.8 per 100,000 in those aged ≥50 years. 6 On the 8 th of April 2021, seven weeks in to Australia's COVID-19 vaccine rollout, ATAGI announced that the Pfizer COVID-19 vaccine was now preferred for adults aged <50 years. 7 Although it did not ban the use of AstraZeneca for those in this younger age group, access to the "non-preferred" vaccine, AstraZeneca, became extremely difficult. At the time, ATAGI acknowledged that "preferring" vaccines for certain age groups would likely impact confidence in the AstraZeneca vaccine in all age groups. 5 Before the change, Australia had purchased 3.8 million doses of AstraZeneca, and 20 million doses of Pfizer 8 -enough vaccines to fully vaccinate 11.9 million Australians (with no vaccine wastage), in a population of approximately 21 million Australian aged ≥16 years 9 and thus able to be vaccinated. The strategy was then to rely on local manufacture of AstraZeneca as the mainstay of the rollout. 8 The day after the program change announcement, the Australian Government announced that they had ordered a further 20 million doses of Pfizer vaccines; 8 however Pfizer supply issues would ultimately hinder the early months of the rollout.

Previously, when Australia's childhood vaccine program has been modified following probable AEFI, confidence and subsequent uptake has dropped. After an increase in febrile seizures in children aged 6-59 months who received a particular brand of an influenza vaccine in 2010, the childhood influenza vaccination program was suspended for four months. Annual coverage declined, most notably in Western Australia 10 where the state government had been funding the vaccine for all children under five. Coverage dropped due to the suspension of vaccine programs, 10 but also because of ensuing hesitancy among both parents and health care workers (HCWs). 11, 12 Coverage has only recently increased following state-based and eventually national influenza vaccine programs and widely reported infant deaths from influenza. 13 There remains, however, a significant gap in knowledge about how Australian adults react to vaccine program changes following a safety signal.

In addition to Australia, several other countries suspended their use of AstraZeneca due to TTS. Data are show that people in France, Germany, Spain and Italy view that vaccine as less safe since the suspension; however, reports of TTS have had little to no impact on the perception of AstraZeneca safety in Britain and Sweden. Populations in all these countries, however, viewed AstraZeneca as less safe than the Moderna and Pfizer COVID-19 vaccines. 14 We sought to understand whether Australia's COVID-19 vaccine program change immediately impacted confidence in the AstraZeneca vaccine held by adults in Perth metropolitan area, Western Australia.

Through our mixed-methods study called "Coronavax: Preparing Community and Government," 15 we commenced in-depth qualitative interviews with adults aged >18 years in the Perth metropolitan area, Western Australia., 2 days after Australia's COVID-19 vaccine program commenced Approximately 2.5 million people live in WA; 1.9 million of these live in the Perth metropolitan area (hereon referred to as Perth). At the time of writing, there have been just over 1,000 confirmed COVID-19 cases in Western Australia since the first case was reported in Australia in early 2020. 16 Recruitment for Coronavax occurred through media releases, word-of-mouth, social networks, and on our website. Participants signed up through a pre-screening survey hosted on REDCap 17, 18 capturing demographic information such as employment, age, gender, comorbidities, household dynamics, highest level of education, religion, country of birth, and language/s spoken at home. Following assessment of whether they fit into our priority groups for interviews, interviews were undertaken by experienced qualitative researchers SJC and LM, and student researcher LR. People prioritised for interview at that time were either HCWs, aged care workers (ACW), aged ≥65 years, or aged 18 -29 years. These particular groups were interviewed first as the Coronavax research team determined in 2020 that they were likely going to be priority groups for vaccination given their high-risk work environments (HCWs and ACWs), susceptibility to severe COVID-19 (those aged ≥65 years), or role in COVID-19 transmission (those aged 18 -29 years). Given the unique opportunity to capture any changes in COVID-19 vaccine intention following changes to the vaccination program, we brought the data together from the three groups for this analysis.

Prior to the ATAGI announcement on the 8 th April 2021, we had undertaken face-to-face, video, or telephone interviews with 31 people, asking about their thoughts on the different COVID-19 vaccines in use. Following the ATAGI announcement, we re-contacted participants (up to three times each) requesting an email or short phone interview on whether the program change altered anything that they told us, or if they had any new thoughts. Audio files were transcribed verbatim; quotes from the first interview were provided during the second interview for participants to comment on if requested.

Using the Framework method for qualitative data analysis, 19 we examined participants' confidence in the AstraZeneca vaccine, comparing participants' attitudes with each other and with their own attitudes before and after the program change. We modified Leask et al's 20 categorisations of parental positions on routine childhood vaccination to apply specifically to the COVID-19 vaccine intentions of adults. We also considered access in our model, which is distinct from a hesitancy barrier 21 but is a crucial consideration for vaccine uptake, especially during a pandemic vaccine rollout where systems need to reach people who may not be regular participants in vaccination programs. The possible positions are outlined in Figure 1 .

SJC undertook the initial assessment of participants' COVID-19 vaccine intentions; all authors reviewed and confirmed them. Tables with full quotes are provided in Supplementary Table 1 for adults aged <50   years, and Supplementary Table 2 for adults aged >50 years.

Committee (RGS0000004457). Participants gave written consent for the first interview and for project researchers to contact them for follow-up. Pseudonyms have been used.

We contacted all 31 participants and obtained data from 28 (90%), within a median response time of eight (5-18) days after the announcement of the program change.

Of the 28 respondents, 18 were aged 23-50 years, 17 were female, four had medical conditions that increased the risk of COVID-19 complications, and one was pregnant. The highest level of education was a postgraduate degree (n=11), with a further nine participants having an undergraduate degree. The majority (26/28) spoke English at home, 16 were Australian born, and six worked in close proximity to patients, and three in aged-care settings.

Adults aged <50 years In our sample of 18 adults aged <50 years, 17 were either already vaccinated with their first dose or intending to be vaccinated when a COVID-19 vaccine was offered to them. We classified seven as COVID-19 vaccine acceptors ( Figure 2 ). For example, Phoebe (female, 28 years) said:

I'm happy to get whatever vaccine I can get, you know, that gives me…a lot more protection again than I had this time last year.

The majority (10/18) of the adults aged <50 years were classified as 'cautious acceptors'-their most common concern was that AstraZeneca was not as effective as Pfizer, or conversely that Pfizer was a "new" technology. For example, Sterling (male, 25 years) said: 

Adults aged <50 years After the program change, 15/17 adults under 50 who were either vaccinated or intending on being vaccinated when offered planned to stay the course, but some shifted to a more hesitant category. Four remained COVID-19 vaccine 'acceptors,' 11 were 'cautious acceptors,' but three were now classified as 'wait awhile' (Figure 2 ). All those who remained acceptors discussed other circumstances they deemed riskier to their health, such as taking the oral contraceptive pill, developing a blood clot from a COVID-19 infection, or influenza vaccination. Annalise (female, 25 years) had said before the program change that she would receive "whichever one I can get" and thus was an acceptor. However, following the program change, Annalise became a 'cautious acceptor' -her doctor advised against AstraZeneca vaccination due to Annalise taking medication against blood clots. She explained: Though many remained 'cautious acceptors,' the reasoning behind caution changed for some.

Many of those who discussed differences in vaccine efficacy turned their attention to the differences in safety, and some discussed how a specific COVID-19 vaccine was now safer. For example, as previously highlighted, Sterling (male, 25 years), originally did not prefer Pfizer due to it being an mRNA vaccine. Thirteen days after the program change, he said:

Those who were classified as 'wait awhile' after the program change had specific concerns about safety due to medical conditions. Margaret said, 16 Interestingly, two of the original acceptors in this age group were either already vaccinated (and thus classified as 'acceptors') or were intending on being vaccinated with their preferred brand ('cautious acceptor'), but nevertheless expressed concern for friends and family members aged <50 years, and thus were also classified as '(hoping others) wait awhile.' For example, Jackie (female, 65 years) originally said:

I'm all for AstraZeneca or any of the others when they get here…as long as the efficacy has been proven.

But in her second interview, Jackie said: Eline (female, 69 years), originally classified as a 'cautious acceptor' described in her second interview how people should have a choice regarding the brand of vaccine they receive. As she would wait to have the Pfizer vaccine, she was classified as 'wait awhile'. Like a younger counterpart, Eline had comorbidities and also a history of reactions to vaccines, and this was likely fuelling her increased hesitancy towards COVID-19 vaccination.

Our study provides important insight into how major changes to COVID-19 vaccine programs may impact vaccine confidence. At the time of the change, the Australian Technical Advisory Group on Immunisation (ATAGI) recognised it may impact confidence, and media articles focused heavily on the risk of blood clots for weeks afterwards. However, our study shows that for adults in Perth, Western

Australia, the majority who intended on vaccinating before the change still intended on vaccinating afterwards, regardless of age. Although many remained 'cautious acceptors', the focus of their caution pivoted from differences in vaccine efficacy to the risk of blood clotting following AstraZeneca vaccination. Several participants also mentioned that they believed influenza vaccination was risker than A major strength of our study was its flexible data collection method; this enabled us to contact participants within a short time frame to ascertain whether or not the change to the COVID-19 vaccine program altered people's intentions regarding vaccination. The main limitation of our study, however, was that the majority of our participants were well-educated (due to our prioritisation of HCWs for interviews at that time), spoke English at home, and did not have any medical conditions that would increase their vulnerability to a severe COVID-19 infection. Given how well-educated our cohort was, they were arguably more in-tune with program changes than the general public. Further research should explore the COVID-19 vaccine intentions of other groups, such as those who are Culturally and Linguistically Diverse, adults with comorbidities, and those who live in regional and remote areas.

Indeed, Coronavax will be interviewing such groups. 15

We have found that there is still high willingness to vaccinate against COVID-19 in Western Australia following a major change to the vaccine program. For those who already had concerns about COVID-19

vaccination, the reason/s for their concern mostly changed from vaccine efficacy differences to vaccine safety differences. The government, health care providers and media spokespeople need to be aware of potential reasons for concern, and to address such concerns to assist those with COVID-19 vaccine intentions. 

Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine

As the pandemic progresses, how does willingness to vaccinate against COVID-19 evolve? International journal of environmental research and public health

Willingness to vaccinate against COVID-19 in Australia. The Lancet Infectious Diseases

COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets

ATAGI statement on COVID-19 vaccination and a reported case of thrombosis

Australian Technical Advisory Group on Immunisation (ATAGI)

Australian Government Department of Health

Department of Health. Australia's vaccine agreements: Australian Government

Australian Bureau of Statistics. National, state and territory population: Australian Government

Influenza disease and vaccination in children in Australia

The impact of a vaccine scare on parental views, trust and information needs: A qualitative study in

The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children

Influenza disease and vaccination in children in Australia

Europeans now see AstraZeneca vaccine as unsafe, following blood clots scare

Preparing Community and Government for COVID-19 Vaccination: a Research Protocol for a mixed-methods social research project

Australian Government Department of Health. Coronavirus (COVID-19) current situation and case numbers

Australian Government

Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support

The REDCap consortium: Building an international community of software platform partners

Using the framework method for the analysis of qualitative data in multi-disciplinary health research

Communicating with parents about vaccination: a framework for health professionals

Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology

Government of Western Australia

COVID-19 vaccine rollout updates [online]. Canberra: Australian Government Department of Health

Communicating with patients and the public about COVID-19 vaccine safety: recommendations from the Collaboration on Social Science in Immunisation

We are grateful for the time and insight our participants shared with us. We would also like to thank our Coronavax Research Coordinator and Project Manager, Dr Sian Tomkinson, and the Coronavax consumer representative, Ms Catherine Hughes, for their support.

 We interviewed adults in Perth, Western Australia, about COVID-19 vaccine intention before and after a change to the vaccine program due to an increased risk of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca  For the majority, intention to vaccinate against COVID-19 did not change; reason for intention did. Before the change, participants were mostly concerned about efficacy, and after the change, the main concern was safety  Crucial for governments, health care providers and media to respond to COVID-19 vaccine safety, efficacy and access concerns.